These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

206 related articles for article (PubMed ID: 25111427)

  • 1. Effect of small molecule vasopressin V1a and V2 receptor antagonists on brain edema formation and secondary brain damage following traumatic brain injury in mice.
    Krieg SM; Sonanini S; Plesnila N; Trabold R
    J Neurotrauma; 2015 Feb; 32(4):221-7. PubMed ID: 25111427
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Role of vasopressin V(1a) and V2 receptors for the development of secondary brain damage after traumatic brain injury in mice.
    Trabold R; Krieg S; Schöller K; Plesnila N
    J Neurotrauma; 2008 Dec; 25(12):1459-65. PubMed ID: 19118456
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Time-Dependent Effects of Arginine-Vasopressin V1 Receptor Inhibition on Secondary Brain Damage after Traumatic Brain Injury.
    Krieg SM; Trabold R; Plesnila N
    J Neurotrauma; 2017 Apr; 34(7):1329-1336. PubMed ID: 27762660
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Arginine vasopressin V1a receptor-deficient mice have reduced brain edema and secondary brain damage following traumatic brain injury.
    Rauen K; Trabold R; Brem C; Terpolilli NA; Plesnila N
    J Neurotrauma; 2013 Aug; 30(16):1442-8. PubMed ID: 23441636
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Selective vasopressin-1a receptor antagonist prevents brain edema, reduces astrocytic cell swelling and GFAP, V1aR and AQP4 expression after focal traumatic brain injury.
    Marmarou CR; Liang X; Abidi NH; Parveen S; Taya K; Henderson SC; Young HF; Filippidis AS; Baumgarten CM
    Brain Res; 2014 Sep; 1581():89-102. PubMed ID: 24933327
    [TBL] [Abstract][Full Text] [Related]  

  • 6. V1a- and V2-type vasopressin receptors mediate vasopressin-induced Ca2+ responses in isolated rat supraoptic neurones.
    Gouzénes L; Sabatier N; Richard P; Moos FC; Dayanithi G
    J Physiol; 1999 Jun; 517 ( Pt 3)(Pt 3):771-9. PubMed ID: 10358117
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Nonpeptide antagonists for vasopressin receptors. Pharmacology of SR 121463A, a new potent and highly selective V2 receptor antagonist.
    Serradeil-Le Gal C
    Adv Exp Med Biol; 1998; 449():427-38. PubMed ID: 10026834
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Vasopressin(4-9) fragment activates V1a-type vasopressin receptor in rat supraoptic neurones.
    Gouzènes L; Dayanithi G; Moos FC
    Neuroreport; 1999 Jun; 10(8):1735-9. PubMed ID: 10501566
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Real-time monitoring of changes in brain extracellular sodium and potassium concentrations and intracranial pressure after selective vasopressin-1a receptor inhibition following focal traumatic brain injury in rats.
    Filippidis AS; Liang X; Wang W; Parveen S; Baumgarten CM; Marmarou CR
    J Neurotrauma; 2014 Jul; 31(14):1258-67. PubMed ID: 24635833
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Sodium excretion in response to vasopressin and selective vasopressin receptor antagonists.
    Perucca J; Bichet DG; Bardoux P; Bouby N; Bankir L
    J Am Soc Nephrol; 2008 Sep; 19(9):1721-31. PubMed ID: 18596120
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The role of vasopressin V1A receptors in cytotoxic brain edema formation following brain injury.
    Kleindienst A; Dunbar JG; Glisson R; Marmarou A
    Acta Neurochir (Wien); 2013 Jan; 155(1):151-64. PubMed ID: 23188468
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Vasopressin V2 (SR121463A) and V1a (SR49059) receptor antagonists both inhibit desmopressin vasorelaxing activity.
    Méchaly I; Laurent F; Portet K; Serrano J; Cros G
    Eur J Pharmacol; 1999 Nov; 383(3):287-90. PubMed ID: 10594321
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Nonpeptide vasopressin receptor antagonists: development of selective and orally active V1a, V2 and V1b receptor ligands.
    Serradeil-Le Gal C; Wagnon J; Valette G; Garcia G; Pascal M; Maffrand JP; Le Fur G
    Prog Brain Res; 2002; 139():197-210. PubMed ID: 12436936
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Modulation of AQP4 expression by the selective V1a receptor antagonist, SR49059, decreases trauma-induced brain edema.
    Taya K; Gulsen S; Okuno K; Prieto R; Marmarou CR; Marmarou A
    Acta Neurochir Suppl; 2008; 102():425-9. PubMed ID: 19388360
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Characterization of SR 121463A, a highly potent and selective, orally active vasopressin V2 receptor antagonist.
    Serradeil-Le Gal C; Lacour C; Valette G; Garcia G; Foulon L; Galindo G; Bankir L; Pouzet B; Guillon G; Barberis C; Chicot D; Jard S; Vilain P; Garcia C; Marty E; Raufaste D; Brossard G; Nisato D; Maffrand JP; Le Fur G
    J Clin Invest; 1996 Dec; 98(12):2729-38. PubMed ID: 8981918
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Safety, tolerability, and pharmacokinetics of SR 49059, a V1a vasopressin receptor antagonist, after repeated oral administration in healthy volunteers.
    Brouard R; Laporte V; Serradeil Le Gal C; Pignol R; Jang H; Donat F; Lockwood G; Fournie D; Dreux F
    Adv Exp Med Biol; 1998; 449():455-65. PubMed ID: 10026839
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Vasopressin V
    Rauen K; Pop V; Trabold R; Badaut J; Plesnila N
    J Neurotrauma; 2020 Feb; 37(4):665-674. PubMed ID: 31547764
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Increased expression of vasopressin v1a receptors after traumatic brain injury.
    Szmydynger-Chodobska J; Chung I; Koźniewska E; Tran B; Harrington FJ; Duncan JA; Chodobski A
    J Neurotrauma; 2004 Aug; 21(8):1090-102. PubMed ID: 15319008
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Arginine-Vasopressin Receptor Blocker Conivaptan Reduces Brain Edema and Blood-Brain Barrier Disruption after Experimental Stroke in Mice.
    Zeynalov E; Jones SM; Seo JW; Snell LD; Elliott JP
    PLoS One; 2015; 10(8):e0136121. PubMed ID: 26275173
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Receptor binding of oxytocin and vasopressin antagonists and inhibitory effects on isolated myometrium from preterm and term pregnant women.
    Akerlund M; Bossmar T; Brouard R; Kostrzewska A; Laudanski T; Lemancewicz A; Serradeil-Le Gal C; Steinwall M
    Br J Obstet Gynaecol; 1999 Oct; 106(10):1047-53. PubMed ID: 10519430
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.